Day 7 blastocyst euploidy supports routine implementation for cycles using preimplantation genetic testing

John B. Whitney¹, Katie Balloch¹, Robert E. Anderson², Nancy Nugent¹, Mitchel C. Schiewe¹

¹Ovation Fertility, ART Lab, Newport Beach, CA 92663 USA
²Southern California Center for Reproductive Medicine, Newport Beach, CA 92663 USA

This study was presented, in part, at both the 32th European Society for Human Reproduction and Embryology conference in Helsinki, Finland, and the 72nd Annual Meeting for the American Society for Reproductive Medicine in Baltimore, MD

ABSTRACT

Objective: To determine if Day 7 blastocysts merit biopsy, vitrification and transfer consideration by contrasting their aneuploidy and implantation rates to Day 5 and 6 blastocysts.

Methods: A total of 1,925 blastocysts were biopsied from 402 PGT-A cycles over a 12 to 16 month interval. All embryos were cultured under tri-gas, humidified conditions (37ºC) for up to 7 days (168 hours post-insemination). Biopsied blastocysts were vitrified and trophectoderm samples analyzed using NextGen sequencing. Single euploid embryo transfers were performed (n=254) using either a Day 5 (n=145), Day 6 (n=92) or a Day 7 blastocyst (n=16) post-warming. Euploidy rates and pregnancy outcomes were subsequently assessed and differences determined by day of development and blastocyst quality grade.

Results: No differences were observed in implantation, pregnancy loss or ongoing pregnancy rates between Day 5 and Day 6 blastocysts. Development to Day 7 accounted for 6.6% of all blastocysts. Euploid rates were higher in Day 5 blastocysts (53.5%; p<0.05) compared to Day 6 (40.4%) and Day 7 (35.9%). High implantation potential (56.3% to 79.3%) of vitrified-warmed euploid blastocyst occurred independent to the day of development. However, miscarriage/loss rates increased (22.2% vs. 2%; p<0.05) with Day 7 blastocysts, resulting in lower (p<0.05) live birth rates (43.8% vs. 67.4-77.2%).

Conclusion: Culturing blastocysts to Day 7 has proven beneficial by achieving viable euploid embryos that would have otherwise been discarded. An extra day of embryo growth allows select patients additional opportunities for in vitro development and possible healthy term live births.

Keywords: embryo culture, Day 7, blastocyst, biopsy, PGT

INTRODUCTION

Human in vitro blastocyst development is highly dependent on variables inherent to the laboratories culture environment (Gardner, 2016; Swain et al., 2016). Environmental factors influencing embryo culture include, but are not limited to, temperature, pH, osmolality, growth promoters, protein supplementation, and the time allowed for development (Kovačić & Vlaisavljević, 2008; Christianson et al., 2014; Swain, 2015; Huang et al., 2016). Current culture interval parameters are broken down by hours post-insemination and typically conclude at 144 hours, or Day 6 (McArthur et al., 2005; Dahdouh et al., 2015). In lieu of the pioneering blastocyst culture efforts of Yves Menézo in the 1990’s, investigators are again questioning if 144 hours of in vitro culture is an accurate measure of developmental potential when implementing routine blastocyst culture for all patients (Kovalevsky et al., 2013; Capalbo et al., 2015). Early human blastocyst culture efforts revealed that Day 7 blastocysts possessed reduced viability, but were capable of creating live births (Veiga et al., 1999; Richter et al., 2006). Ultimately, a healthy baby is the end goal for any patient choosing to invest time, money and emotion into assisted reproductive technologies (Heijnen et al., 2004). Yet, for this goal to be realized a blastocyst must first be available.

The capability of the modern embryology lab has been revolutionized by the adoption of vitrification to reliably cryopreserve human blastocysts (Kuwayama et al., 2005; Loutradi et al., 2008; Schoolcraft & Katz-Jaffe, 2013; Schiewe et al., 2015; Gardner, 2016). Emphasis on the implementation of vitrification-all cycles to optimize uterine receptivity (Shapiro et al., 2011; Desai et al., 2016), and in conjunction with preimplantation genetic testing for aneuploidy screening (PGT-A; Whitney et al., 2016) has placed pressure on the IVF laboratory to efficiently produce blastocysts (Roque et al., 2015; Desai et al., 2016). Culture environment, specifically the type and conditioning of culture media, has been emphasized to maximize blastocyst yield per cycle and improve outcomes (Swain, 2015). Menezo’s blastocyst culturing efforts with Day 7 embryos has seemingly been ignored by improvements in embryo culture medium. The acceptable timing for blastocyst development is portrayed as a fixed variable not usually evaluated beyond 144 hours (Barash et al., 2017).

An embryos ability to cleave and blastulate in an organized, predictable manner, as an indicator of developmental potential, does not guarantee normal chromosomal constitution or implantation. Current technologies implementing PGT-A have exhibited improvements in clinical pregnancies and live birth rates compared to untested first-time embryo transfers (Whitney et al., 2016). Some studies have also postulated that a quicker time to blastulation to be a predictor for implantation (Desai et al., 2016), as well as slower blastocyst development correlating to higher aneuploidy (Kovalevsky et al., 2013). Given the complexity required to accurately choose a single embryo for transfer, we question whether todays’ standard lab practices of 144 hr in vitro culture could be eliminating potentially viable embryos. Fundamentally, we questioned to what extent viable, euploid blastocysts can still be effectively produced by continuing culture an additional 24 hours to 168 hours post-insemination (Day 7).
MATERIALS AND METHODS

Population
Patients, averaging 37.3 years of age, electively chose IVF treatment with PGT-A of all viable embryos at a single IVF center/ART lab. All cycles performed standard controlled ovarian hyperstimulation protocols, established embryo culture practices, and intracytoplasmic sperm injection (ICSI). Cycles initiated January 1st, 2015 to March 1st, 2016 were enrolled in an observational study to assess Day 7 blastocyst aneuploidy and implantation potential. Patients were not aware of genetic outcomes and the transfer selection was made by patient preference or available top quality euploid embryo. No randomization or control treatments were performed as this was a retrospective observational analysis of standard IVF applications following informed patient consent and prior Institutional Review Board approval.

Embryo Culture and Blastocyst Grading
Using MCO-5M mini Sanyo/Panasonic tri-gas incubators (5% O2/5.3-6.0% CO2), we grouped cultured up to 5 embryos per 25μL droplet of GlobalTM medium (LG; Life Global, Guilford, CT) supplemented with 7.5% synthetic protein supplement under OvoilTM (Vitrolife, Englewood, CO) until blastocyst biopsy (Whitney et al., 2016). All oocytes retrieved were evaluated for maturity and had ICSI performed 2-6 hours post-egg retrieval. Embryos were initially evaluated at 14-18 hours post-insemination for fertilization. All embryos exhibiting normal 2PN fertilization and all failed fertilization (OPN) zygotes were cultured an additional 48 hours. On Day 3, 72 hours post-egg retrieval, embryos were evaluated for cleavage development and quality. All cleaved embryos having 3 cells or more were laser zona dissected using a 1410-nm diode laser (Zilos-tkTM; Hamilton Thorne, Beverly, MA) and embryo incubation continued an additional 48 hours to Day 5 (Whitney et al., 2015). At 120 hours post-egg retrieval, or Day 5, all embryos were assessed for blastocyst development and quality graded (QS) using a modified Gardner system (Whitney et al., 2015). In short, pre-terminally hatching blastocysts were classified as QG3 = <10% trophectoderm hatching, QG4=10-50% hatching and QG5 =50% hatching. Full blastocysts (QG3), expanded blastocysts (QG4), hatching blastocysts (QG5) and hatched blastocysts (QG6) were biopsied and vitrified. Inner cell mass (ICM) and trophectoderm were independently graded from top quality “A” (excellent) to good-fair quality “B” and fair-poor quality “C” with the first letter in the grade assigned to the ICM and the second to trophectoderm (Gardner & Schoolcraft, 1999). In brief, “A” ICM possess numerous, tightly packed cells, while “A” trophectoderm have a highly cellular, cohesive layer free of irregularities. “B” and “C” quality ICM and trophectoderm possess fewer, more loosely conjoined cells, as well as varying levels of notable defects and unincorporated cells. Typically, a grade of 3BB or better was required to initiate biopsy, however lower quality blastocysts possessing a “C” grade may have been incorporated into patient sub-groups, especially in patients possessing few blastocysts. Embryos not achieving the minimum full blastocyst stage on Day 5 were cultured an additional 24 to 48 hours. Embryos were only assessed once between 6am-12pm. At 144 hours, or Day 6, the same evaluation was performed and blastocysts biopsied. If any of the remaining cohort of embryos had at minimum a morula, all embryos continued an additional 24 hours of in vitro culture. A final assessment was made 168 hours post-ICSI, or Day 7, which was equivalent to 206 to 210 hours post-hCG administration. All embryos not achieving a full blastocyst stage were discarded. All biopsied embryos were vitrified pending PGT-A results.

Blastocyst Biopsy and PGT-A
The zona opening created on Day 3 allowed trophoderm to prematurely rupture through a 10-12µm furrow in the zona. The Zilos-tkTM laser was used for biopsying, as reported previously (Whitney et al., 2016). In short, a combination of laser pulses and mechanical separation was applied to isolate 3-10 trophoderm cells. All biopsy samples were aseptically pipetted into individual PCR tubes, frozen, shipped on dry ice and analyzed for PGT-A using Next Generation Sequencing at either Genesis Genetics (Plymouth, MI) or Ovation Fertility Genetics (Henderson, NV). Both facilities used the VeriSeq platform (Illumina, San Diego, CA). Confirmed euploidy results were required to proceed with a vitrified-warmed embryo transfer. All aneuploid embryos were discarded and removed from frozen inventory per patient consent. Mosaic profiles were reported as aneuploid according to standard lab calling policies and no mosaic outcome embryos were electively transferred.

Day 7 blastocyst euploidy supports
Blastocysts were vitrified using microSecure-VTF in glycerol/EG, non-DMSO VTF solutions (Innovative Cryo Enterprises, Linden, NJ; Schiewe et al., 2015; 2017). Aseptic microSecure VTF was performed using: a 3-step dilution (5 min/5min/1min); individual blastocysts were loaded into 300 µm ID flexipettes (Cook Medical, Spencer, IN; 3 µl volume); flexipettes were then dried and inserted tip first into prelabeled 0.3ml CBS® embryo straws; the straw weld sealed; and plunged directly into LN2, (Schiewe et al., 2015). Rapid warming was achieved by direct placement of the vitrified flexipettes into a 37°C 0.5M sucrose bath (see video: Schiewe et al., 2017). Within 10 sec, each blastocyst was pipetted directly from the flexipette into an open 200 µl droplet of 1.0M sucrose solution and then transferred into 100 µl droplets under oil for 3min intervals. Embryos were serially diluted in declining sucrose solutions (T1-T4; 3 min/step at 21°C), before isotoxic equilibration in Hepes-LG medium (5 min at 37°C). Warmed blastocysts were then cultured in LG medium + protein for 1-3 hr prior to vitrified ET (VFET). As long as blastocysts were osmotically reactive to post-warming dilutions and appeared viable, re-expansion was not a requirement for ET to proceed.

All VFET cycles involved hormone replacement cycles using oral estradiol, estradiol patches or intramuscular (i.m.) estradiol valerate followed by i.m. progesterone in oil. Progesterone in oil was started when endometrial thickness was > 8mm after documentation of serum progesterone level of <1.0 ng/ml. VFET was performed after 5.5 Days of intramuscular progesterone administration. All transvaginal ultrasound guided ET procedures were performed by a single physician (Anderson et al., 2002). Pregnancies were initially tested 10d post-ET and implantation subsequently assessed by transvaginal ultrasound beginning 4 weeks later. Live births were confirmed by written or oral communication with patients.

Statistical Analysis
Blastocyst development was calculated by the successful biopsy of a blastocyst on Day 5, 6 or 7 per 2PN achieved from a single patient retrieval cycle (Table 1). Aneuploidy percentages were determined by the total euploid reported minus the total tested for each day of culture. Initial comparisons for implantation, clinical pregnancies, live births and spontaneous abortions were calculated per transfer attempt (Table 2). Additionally, data were further sub-divided by blastocyst quality grades (Table 3). Chi-squared analyses were performed to contrast differences (p<0.05) in blastocyst development, aneuploidy, implantation and live birth outcomes.


### RESULTS

A total of 1,925 blastocyst embryos were biopsied between the months of January and December of 2015. Blastocyst biopsy was performed on Day 5, 6 and 7 of embryonic development. With a preference toward antagonist stimulated cycles, a mean of 13.1 mature oocytes (MII) per-cycle was produced with a normal fertilization rate of 75% and an average yield of 9.9 zygotes per-cycle for culture to the blastocyst stage. Originating from 315 cycles, 887 (46%) of the blastocysts were euploid after PGT-A determination (Table 1). Ninety-two percent of the cycles performed resulting in 187 implantations (74%) and 181 total of 253 single euploid embryo transfers (SEETs) were created a blastocyst for PGT-A determination, with an average of 2.3 euploid blastocysts per-cycle tested. A normal embryo was produced in 77% of the IVF cycles, with an average of 6.6 blastocysts tested per biopsy patient. A total of 1,925 blastocyst embryos were biopsied and vitrified on either Day 5, 6 or 7 of in vitro culture (Table 2).

| Grade Day 5 Day 6 Day 7* |
|--------------------------|
| # Grade AA | 556 | 330 | 19 |
| # Euploid | 325 | 165 | 12 |
| % Euploid 58.5%<sup>a</sup> 50.0%<sup>b</sup> 63.2% |
| # Grade AB | 161 | 146 | 16 |
| # Euploid | 62 | 54 | 7 |
| % Euploid 38.5% 37.0% 43.8% |
| # Grade BA | 78 | 166 | 22 |
| # Euploid | 46 | 69 | 9 |
| % Euploid 59.0%<sup>a</sup> 41.6%<sup>b</sup> 40.9% |
| # Grade BB | 77 | 220 | 41 |
| # Euploid | 33 | 62 | 15 |
| % Euploid 42.9%<sup>a</sup> 28.2%<sup>b</sup> 36.6% |
| # Grade BC | 2 | 17 | 5 |
| # Euploid | 0 | 5 | 0 |
| % Euploid 0.0% 29.4% 0.0% |
| # Grade CB | 3 | 24 | 19 |
| # Euploid | 2 | 8 | 2 |
| % Euploid 66.7% 33.3% 10.5% |
| # Grade CC | 0 | 3 | 1 |
| # Euploid | 0 | 2 | 0 |
| % Euploid 0.0% 66.7% 0.0% |
| # Grade CA | 1 | 10 | 5 |
| # Euploid | 1 | 5 | 1 |
| % Euploid 100.0% 50.0% 20.0% |
| # Grade AC | 1 | 2 | 0 |
| # Euploid | 1 | 1 | 0 |
| % Euploid 0.0% 50.0% 0.0% |

<sup>a</sup> Row values with different superscripts are different (<p>0.05).

### Table 1. Blastocyst development and euploidy status by day of in vitro culture

| Grade | Day 5 | Day 6 | Day 7 |
|-------|-------|-------|-------|
| # Biopsied | 879 | 918 | 128 |
| % Blastocyst Yield | 45.7%<sup>a</sup> 47.7%<sup>b</sup> 6.6% |
| # Normal | 470 | 371 | 46 |
| % Euploid | 53.5%<sup>a</sup> 40.4%<sup>b</sup> 35.9%<sup>b</sup> |

<sup>a,b</sup> Row values with different superscripts are different (<p>0.05).

### Table 2. Pregnancy outcomes of euploid blastocysts biopsied and vitrified on either Day 5, 6 or 7 of in vitro culture

| # of Embryos Transferred | Day 5 | Day 6 | Day 7 |
|--------------------------|-------|-------|-------|
| 145 | 92 | 16 |
| # of Implantations | 115 | 63 | 9 |
| Implantation Rate | 79.3% 68.5% 56.3% |
| Spontaneous Abortion Rate | 2.6%<sup>a</sup> (3/115)<sup>a</sup> 1.6%<sup>a</sup> (1/63)<sup>a</sup> 22.2%<sup>a</sup> (2/9)<sup>a</sup> |
| Live birth rates | 77.2%<sup>a</sup> (112/145)<sup>a</sup> 67.4%<sup>a</sup> (62/92)<sup>a</sup> 43.8%<sup>a</sup> (7/16)<sup>a</sup> |

<sup>a,b</sup> Combined row values with different superscripts, within sub-sections, were different (<p>0.05).
blastocyst development or quality grade, respectively. On Day 7, 42% of the embryos were fully hatched, 38% classified as hatching (QG=5) and 23% exhibited progressive herniation of the trophectoderm as grade 3 and 4 blastocysts.

**DISCUSSION**

Modern embryology methods have placed an emphasis on optimizing in vitro embryo culture conditions to produce more fast growing, higher quality, physiologically normal blastocysts (Gardner, 1998; Wale & Gardner, 2016). Current societal and industry pressures for single embryo transfers have increased the need for accurate selection criteria to best optimize pregnancy outcomes (Yang et al., 2012). Our study identifies that in vitro blastocyst development may initiate between 96 and 172 hours post-insemination with emphasis on Day 5, or 120 hours post-insemination, top morphologically graded blastocysts (Barash et al., 2017). This long held philosophy was supported by our data, but not definitively so. Our study indicates Day 5 blastocysts with "A" quality trophectoderm produce higher euploidy rates, further supporting previous assertions that an "A" trophectoderm grade is more predictive of pregnancy success than ICM grades (Ahlström et al., 2013; Whitney et al., 2015). Although euploidy on Day 5 is increased, this study indicates that ploidy status is the definitive value for implantation success, not the day of development.

Our study supports the observations of Capalbo et al. (2014, 2015) relative to the importance of morphology and developmental progress, with the implantation potential of euploid blastocysts being independent of morphology and in vitro culture interval. Both groups observed no difference in implantation for euploid embryos generated on Day 5, 6 or 7. The differences observed in Day 7 euploidy rates between Capalbo et al. (2014) and our investigation (43.5% vs. 35.9%, respectively), may simply reflect our willingness to have biopsied more poor quality embryos. In either case, we achieved similar ongoing implantation/live birth outcomes using euploid Day 7 blastocysts (50% to 42.8%), which was significantly better than that of untested Day 7 blastocysts (27%; Kovalevsky et al., 2013). In contrast to the valuable multi-center/multi-physician observational studies of Capalbo et al. (2014, 2015), the higher overall implantation success observed in our study on Days 5 and 6 may reflect a benefit to reduced confounding procedural variables associated with a single physician IVF center. In the laboratory, differences in our VTF procedure (i.e., use of a non-DMSO solution; Schiewe et al., 2015) or perhaps biopsy technique (i.e., Day 3 pre-laser zona dissection; Whitney et al., 2016) may have benefited embryo well-being. In particular, we hypothesize that recently biopsied trophectodermal cells may be susceptible to DMSO exposure adversely affecting their normal functionality, without a pre-VTF equilibration period (>2 to 3 hours). We believe that glycerol/EG may be a safer and more effective VTF solution for blastocysts. In this study, SEET procedures were performed without regard to whether blastocyst re-expansion post-warming occurred. Further investigations focused on post-biopsy pre-VTF equilibration intervals and post-warming blastocyst re-expansion time could add to our understanding of the developmental competence and implantation potential of PGT-A tested blastocysts.

Although human blastocysts can sustain in vitro development up to Day 14 (Edwards et al., 1981; Shahbazi et al., 2016), they typically initiate implantation (i.e., attachment) by Day 8 (Shahbazi et al., 2016). Therefore, it is reasonable to assume that Day 7 is the last day our current static culture environment should sustain pre-transfer embryo growth. Not surprisingly, Day 7 blastocyst yield is significantly reduced in comparison to Day 5 and 6, yet Day 7 euploid blastocysts have proven viable and implanted. Considering human trophectoderm cells are programmed to invade the endometrium upon hatching, theoretically, the more robust the trophectoderm the greater its chance to initiate pregnancy (Ahlström et al., 2013). Day 7 blastocysts can potentially promote implantation but are vulnerable to increased pregnancy loss, perhaps due to a lack of cellular vigor to offset their delayed growth or trophectoderm degeneration due to the extended length of culture. Additionally, our low patient numbers may not have accurately reflected the situation, or perhaps uterine asynchrony may have contributed to the problem warranting a possible change in the luteal support protocol when transferring a Day 7 blastocyst.

Ten patients achieved a transferable euploid embryo that would have been otherwise discarded if we did not grow their embryo(s) to Day 7. Over a 14-month interval, this study yielded 3 healthy term births, without complications or known abnormalities, which would not have been available under previous treatment protocols with culture ending at 144 hours. Our results support Yves Menezo’s original assertion of the potential merits obtained applying Day 7 blastocyst culture. Furthermore, as shown by Capalbo et al. (2014, 2015), the routine implementation of Day 7 culture is particularly important for IVF cycles experiencing delayed blastocyst development, such as vitrified-warmed oocyte cycles, or any cycle seeking aneuploidy determination following substandard Day 6 development. We acknowledge the euploidy rate and embryo yield from Day 7 is low and requires additional staff time and effort. Nonetheless, our goal in the IVF lab is to afford our patient’s every opportunity for a live birth, and Day 7 culture has proven beneficial to achieve this objective.

**Conflict of Interests**

The authors declare that there is no conflict of interest.

**Support:** This study was fully supported by internal research funding at Ovation Fertility.

**Corresponding Authors:**

John B. Whitney
Ovation Fertility, ART Lab
Newport Beach, CA 92663 USA
Email: jwhitney@ovationfertility.com

Mitchel C. Schiewe
Ovation Fertility, ART Lab
Newport Beach, CA 92663 USA
Email: mschiewe@ovationfertility.com

**REFERENCES**

Ahlström A, Westin C, Wikland M, Hardarson T. Prediction of live birth in frozen-thawed single blastocyst transfer cycles by pre-freeze and post-thaw morphology. Hum Reprod. 2013;28:1199-209. PMID: 23477908 DOI: 10.1093/humrep/det054

Anderson RE, Nugent NL, Gregg AT, Nunn SL, Behr BR. Transvaginal ultrasound-guided embryo transfer improves outcome in patients with previous failed in vitro fertilization cycles. Fertil Steril. 2002;77:769-75. PMID: 11937132 DOI: 10.1016/S0015-0282(01)03279-4
Barash OO, Ivani KA, Willman SP, Rosenbluth EM, Wachs DS, Hinckley MD, Pittenger Reid S, Weckstein LN. Association between growth dynamics, morphological parameters, the chromosomal status of the blastocysts, and clinical outcomes in IVF PGS cycles with single embryo transfer. J Assist Reprod Genet. 2017;34:1007-16. PMID: 28560610 DOI: 10.1007/s10815-017-0944-0

Capalbo A, Rienzi L, Cimadomo D, Maggiulli R, Elliott T, Wright G, Nagy ZP, Ubaldi FM. Correlation between standard blastocyst morphology, euploidy and implantation: an observational study in two centers involving 956 screened blastocysts. Hum Reprod. 2014;29:1173-81. PMID: 24578475 DOI: 10.1093/humrep/deu033

Capalbo A, Ubaldi FM, Cimadomo D, Maggiulli R, Patassini C, Dusi L, Sanges F, Buffo L, Venturella R, Rienzi L. Consistent and reproducible outcomes of blastocyst biopsy and aneuploidy screening across different biopsy practitioners: a multicentre study involving 2586 embryo biopsies. Hum Reprod. 2015;31:199-208. PMID: 26637492 DOI: 10.1093/humrep/dev294

Christianson MS, Zhao Y, Shoham G, Granot I, Safran A, Khafagy A, Leong M, Shoham Z. Embryo catheter loading and embryo culture techniques: results of a worldwide Web-based survey. J Assist Reprod Genet. 2014;31:1029-36. PMID: 24913025 DOI: 10.1007/s10815-014-0250-z

Dahdouh EM, Balayla J, García-Velasco JA. Comprehensive chromosome screening improves embryo selection: a meta-analysis. Fertil Steril. 2015;104:1503-12. PMID: 26385405 DOI: 10.1016/j.fertnstert.2015.08.038

Desai N, Ploskonka S, Goodman L, Attaran M, Goldberg JM, Austin C, Dusi L, Sanges F, Buffo L, Venturella R, Rienzi L. Consistent and reproducible outcomes of blastocyst biopsy and aneuploidy screening across different biopsy practitioners: a multicentre study involving 2586 embryo biopsies. Hum Reprod. 2015;31:199-208. PMID: 26637492 DOI: 10.1093/humrep/dev294

Edwards RG, Purdy JM, Steptoe PC, Walters DE. The growth of human preimplantation embryos in vitro. Am J Obstet Gynecol. 1981;141:408-16. PMID: 7282823 DOI: 10.1016/0002-9378(81)90603-7

Gardner DK. Changes in requirements and utilization of nutrients during mammalian preimplantation embryo development and their significance in embryo culture. Theriogenology. 1998;49:83-102. PMID: 10732123 DOI: 10.1016/S0093-691X(97)00404-4

Gardner DK. The impact of physiological oxygen during culture, and vitrification for cryopreservation, on the outcome of extended culture in human IVF. Reprod Biomed Online. 2016;32:137-41. PMID: 26687905 DOI: 10.1016/j.rbmo.2015.11.008

Gardner DK, Schoolcraft WB. In vitro culture of human blastocyst. In: Jansen R, Mortimer D, eds. Towards Reproductive Certainty: Fertility and Genetics Beyond. Carnforth: Parthenon Publishing; 1999. p. 378-88.

Heijnen EM, Macklon NS, Fauser BC. What is the most relevant standard of success in assisted reproduction? The next step to improving outcomes of IVF: consider the whole treatment. Hum Reprod. 2004;19:1936-8. PMID: 15217998 DOI: 10.1093/humrep/deh368

Huang J, Chen H, Lu X, Wang X, Xi H, Zhu C, Zhang F, Lv J, Ge H. The effect of protein supplement concentration in embryo transfer medium on clinical outcome of IVF/ICSI cycles: a prospective, randomized clinical trial. Reprod Biomed Online. 2016;32:79-84. PMID: 26611500 DOI: 10.1016/j.rbmo.2015.10.004

Kovačić B, Vlaisavljević V. Influence of atmospheric versus reduced oxygen concentration on development of human blastocysts in vitro: a prospective study on sibling oocytes. Reprod Biomed Online. 2008;17:229-36. PMID: 18681997 DOI: 10.1016/S1472-6483(10)60199-X

Kovalevsky G, Carney SM, Morrison LS, Boylan CF, Neithardt AB, Feinberg RF. Should embryos developing to blastocysts on day 7 be cryopreserved and transferred? an analysis of pregnancy and implantation rates. Fertil Steril. 2013;100:1088-12. PMID: 23876530 DOI: 10.1016/j.fertnstert.2013.06.021

Kuwawaya M, Vajta G, Kato O, Leibo SP. Highly efficient vitrification method for cryopreservation of human oocytes. Reprod Biomed Online. 2005;11:300-8. PMID: 16176668 DOI: 10.1016/S1472-6483(10)60837-1

Loutradi KE, Kolibianakis EM, Venetis CA, Papanikolaou EG, Pados G, Bontis I, Tarlatzis BC. Cryopreservation of human embryos by vitrification or slow freezing: a systematic review and meta-analysis. Fertil Steril. 2008;90:186-93. PMID: 17980870 DOI: 10.1016/j.fertnstert.2007.06.010

McArthur SJ, Leigh D, Marshall JT, de Boer KA, Jansen RP. Pregnancies and live births after trophectoderm biopsy and preimplantation genetic testing of human blastocysts. Fertil Steril. 2005;84:1628-36. PMID: 16359956 DOI: 10.1016/j.fertnstert.2005.05.063

Richter KS, Shipley SK, McVeary I, Tucker MJ, Widra EA. Cryopreserved embryo transfers suggest that endometrial receptivity may contribute to reduced success rates of later developing embryos. Fertil Steril. 2006;86:862-6. PMID: 16935284 DOI: 10.1016/j.fertnstert.2006.02.114

Roque M, Valle M, Guimarães F, Sampaio M, Geber S. Freeze-all policy: fresh vs. frozen-thawed embryo transfer. Fertil Steril. 2015;103:1190-3. PMID: 25747130 DOI: 10.1016/j.fertnstert.2015.01.045

Schiewe MC, Zozula S, Anderson RE, Fahy GM. Validation of microSecure vitrification (µS-VTF) for the effective cryopreservation of human embryos and oocytes. Cryobiol. 2015;71:264-72. PMID: 26210008 DOI: 10.1016/j.cryobiol.2015.07.009

Schiewe MC, Zozula S, Nugent N, Waggoner K, Borba J, Gamboa L, Whitney JB. Modified microSecure vitrification: a safe, simple and highly effective cryopreservation procedure for human blastocysts. J Vis Exp. 2017;121:e54871. PMID: 28287560 DOI: 10.3791/54871

Schoolcraft WB, Katz-Jaffe MG. Comprehensive chromosome screening of trophectoderm with vitrification facilitates elective single-embryo transfer for infertile women with advanced maternal age. Fertil Steril. 2013;100:615-9. PMID: 23993664 DOI: 10.1016/j.fertnstert.2013.07.1972
Shahbazi MN, Jedrusik A, Vuoristo S, Recher G, Hupalowska A, Bolton V, Fogarty NNM, Campbell A, Devito L, Ilic D, Khalaf Y, Niakan KK, Fishel S, Zernicka-Goetz M. Self-organisation of the human embryo in the absence of maternal tissue. Nat Cell Biol. 2016;18:700-8. PMID: 27144686 DOI: 10.1038/ncb3347

Shapiro BS, Daneshmand ST, Garner FC, Aguirre M, Hudson C, Thomas S. Evidence of impaired endometrial receptivity after ovarian stimulation for in vitro fertilization: a prospective randomized trial comparing fresh and frozen-thawed embryo transfer in normal responders. Fertil Steril. 2011;96:344-8. PMID: 21737072 DOI: 10.1016/j.fertnstert.2011.05.050

Swain JE. Optimal human embryo culture. Semin Reprod Med. 2015;33:103-17. PMID: 25734348 DOI: 10.1055-s-0035-1546423

Swain JE, Carrell D, Cobo A, Meseguer M, Rubio C, Smith GD. Optimizing the culture environment and embryo manipulation to help maintain embryo developmental potential. Fertil Steril. 2016;105:571-87. PMID: 26851765 DOI: 10.1016/j.fertnstert.2016.01.035

Veiga A, Torelló MJ, Ménezé Y, Busquets A, Sarrias O, Coroleu B, Barri PN. Use of co-culture of human embryos on Vero cells to improve clinical implantation rate. Hum Reprod. 1999;14:112-20. PMID: 10690807 DOI: 10.1093/humrep/14.suppl_2.112

Wale PL, Gardner DK. The effects of chemical and physical factors on mammalian embryo culture and their importance for the practice of assisted human reproduction. Hum Reprod Update. 2016;22:2-22. PMID: 26207016 DOI: 10.1093/humupd/dmv034

Whitney JB, Anderson RE, Nugent NL, Schiewe MC. Euploidy predictability of human blastocyst inner cell mass and trophectoderm grading. Annals Clin Lab Res. 2015;3:4-7. DOI: 10.21767/2386-5180.10004

Whitney JB, Schiewe MC, Anderson RE. Single center validation of routine blastocyst biopsy implementation. J Asst Reprod Genet. 2016;33:1507-13. PMID: 27544278 DOI: 10.1007/s10815-016-0792-3

Yang Z, Liu J, Collins GS, Salem SA, Liu X, Lyle SS, Peck AC, Sills ES, Salem RD. Selection of single blastocysts for fresh transfer via standard morphology assessment alone and with array CGH for good prognosis IVF patients: results from a randomized pilot study. Mol Cytogenet. 2012;5:24. PMID: 22551456 DOI: 10.1186/1755-8166-5-24